288 related articles for article (PubMed ID: 18056006)
1. Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia.
Fuster JL; Bermúdez M; Galera A; Llinares ME; Calle D; Ortuño FJ
Haematologica; 2007 Dec; 92(12):1723-4. PubMed ID: 18056006
[TBL] [Abstract][Full Text] [Related]
2. Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Nishii K; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Haematologica; 2008 Feb; 93(2):287-90. PubMed ID: 18223280
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K
Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435
[TBL] [Abstract][Full Text] [Related]
4. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005.
Rives S; Estella J; Gómez P; López-Duarte M; de Miguel PG; Verdeguer A; Moreno MJ; Vivanco JL; Couselo JM; Fernández-Delgado R; Maldonado M; Tasso M; López-Ibor B; Lendínez F; López-Almaraz R; Uriz J; Melo M; Fernández-Teijeiro A; Rodríguez I; Badell I
Br J Haematol; 2011 Sep; 154(5):600-11. PubMed ID: 21707583
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
Bassan R; Rossi G; Pogliani EM; Di Bona E; Angelucci E; Cavattoni I; Lambertenghi-Deliliers G; Mannelli F; Levis A; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Borghero C; Romani C; Spinelli O; Tosi M; Oldani E; Intermesoli T; Rambaldi A
J Clin Oncol; 2010 Aug; 28(22):3644-52. PubMed ID: 20606084
[TBL] [Abstract][Full Text] [Related]
6. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Burke MJ; Cao Q; Trotz B; Weigel B; Kumar A; Smith A; Verneris MR
Pediatr Blood Cancer; 2009 Dec; 53(7):1289-94. PubMed ID: 19731318
[TBL] [Abstract][Full Text] [Related]
8. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
9. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Nishiwaki S; Miyamura K; Kato C; Terakura S; Ohashi K; Sakamaki H; Nakao S; Harigae H; Kodera Y
Anticancer Res; 2010 Jun; 30(6):2415-8. PubMed ID: 20651401
[TBL] [Abstract][Full Text] [Related]
10. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
11. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.
Piccaluga PP; Malagola M; Rondoni M; Amabile M; Paolini S; Soverini S; Gaitani S; Visani G; Baccarani M; Martinelli G
Eur J Haematol; 2004 Apr; 72(4):302-3. PubMed ID: 15089772
[No Abstract] [Full Text] [Related]
12. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia.
Yamada K; Yasui M; Kondo O; Sato M; Sawada A; Kawa K; Inoue M
Pediatr Blood Cancer; 2013 Aug; 60(8):E60-2. PubMed ID: 23468187
[TBL] [Abstract][Full Text] [Related]
14. Administration of imatinib in the first 90 days after allogeneic hematopoietic cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Shi HX; Han W; Zhan XH; Wang Y; Zhao T; Huang XJ
Chin Med J (Engl); 2011 Jan; 124(2):246-52. PubMed ID: 21362375
[TBL] [Abstract][Full Text] [Related]
15. Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.
Fruehauf S; Topaly J; Buss EC; Schad M; Goerner M; Zeller WJ; Ho AD
Haematologica; 2002 Dec; 87(12):ECR38. PubMed ID: 12495909
[No Abstract] [Full Text] [Related]
16. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Tanguy-Schmidt A; Rousselot P; Chalandon Y; Cayuela JM; Hayette S; Vekemans MC; Escoffre M; Huguet F; Réa D; Delannoy A; Cahn JY; Vernant JP; Ifrah N; Dombret H; Thomas X
Biol Blood Marrow Transplant; 2013 Jan; 19(1):150-5. PubMed ID: 22960387
[TBL] [Abstract][Full Text] [Related]
17. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim DW; Cho BS; Yoon JH; Shin SH; Yahng SA; Lee SE; Eom KS; Kim YJ; Chung NG; Kim HJ; Min CK; Lee JW; Min WS; Park CW
Leukemia; 2012 Nov; 26(11):2367-74. PubMed ID: 22705993
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
19. Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shin HJ; Chung JS; Cho GJ
Bone Marrow Transplant; 2005 Nov; 36(10):917-8. PubMed ID: 16113662
[No Abstract] [Full Text] [Related]
20. Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Li Y; Qiu L; Zou D; Zhao Y; Mi Y; Wang J
Ann Hematol; 2009 Nov; 88(11):1069-77. PubMed ID: 19277658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
